Herpes Vaccination Linked to Reduced Risk of Heart Attack and Stroke,Major study Finds

A groundbreaking new study reveals that vaccination against herpes zoster,commonly known as shingles,may significantly reduce the risk of cardiovascular events like stroke,heart attack,and heart failure.

For decades, the zoster vaccination has been primarily recognized for its protective benefits against the painful rash of shingles. However, research published May 5, 2025, in the European Heart journal by a team at Kyung Hee University in Seoul, South Korea, suggests a far broader impact on health. The study, based on data from over two million individuals, indicates a considerable link between herpes zoster vaccination and improved cardiovascular outcomes.

Long-Term Protection Against Cardiovascular Disease

The extensive,twelve-year study – spanning from January 1,2012,to January 31,2024 – focused on individuals aged 50 and over. Researchers found that those who received the zoster vaccine experienced a 23% reduction in cardiovascular events, reflected in a hazard ratio of 0.77. This protective effect persisted for up to eight years, with the most significant benefits observed within the first two to three years post-vaccination.

“This research demonstrates a compelling correlation between herpes zoster vaccination and a decreased risk of serious cardiovascular problems,” a senior researcher stated.

Did you know? – shingles is caused by the varicella-zoster virus, the same virus that causes chickenpox. After you recover from chickenpox, the virus can remain inactive in your body for years before reactivating as shingles.

Addressing Health Disparities

The benefits of the zoster vaccine appeared particularly pronounced in specific populations. The study revealed a greater decline in cardiovascular risk among men, individuals under the age of 60, and those with less healthy lifestyles – including smokers, those who consume alcohol regularly, and individuals who do not engage in regular exercise.

importantly, the positive effects were even more noticeable in people from “low-income households and in rural areas,” suggesting the vaccine could play a role in mitigating health inequalities. According to the study authors, vaccination may help compensate for systemic disparities in healthcare access and outcomes.

Pro tip: – The CDC recommends that healthy adults 50 years and older get two doses of the recombinant zoster vaccine (Shingrix), even if they’ve had shingles before or received the older live zoster vaccine (Zostavax).

Implications for Germany and Beyond

The findings offer a glimmer of hope in the fight against cardiovascular diseases, which remain the leading cause of death globally. In Germany, data from the Federal Statistical Office show that diseases of the circulatory system accounted for 33.9 percent of all deaths in 2023.

Though, researchers caution against broad generalizations. “Since this study is based on an Asian cohort, the results may not be transferable to all population groups,” a press release from the Kyung Hee University team noted. Further investigation is needed to determine the extent to which these findings apply to diverse populations.

Future Research and Vaccine Growth

The current study utilized the live zoster vaccine, which is not suitable for all individuals. Researchers are now focusing on the recombinant vaccine, a newer formulation, to determine if it offers similar cardiovascular benefits. They also plan to analyse the effects of different vaccine types to understand the broader implications for heart disease prevention.

“Further research on the recombinant vaccine is required, as the zoster living vaccine is not suitable for everyone,” researchers explained.

Reader question: – If I’ve already had shingles, should I still get the vaccine?

Interestingly, this isn’t the first time a vaccine has demonstrated unexpected benefits beyond its primary purpose. Recent studies suggest that corona vaccination may also reduce the risk of strokes.

The study, titled “Live Zoster Vaccination and Cardiovascular Outcomes: A Nationwide, South Korean Study,” was authored by Sooji Lee, Kyeongmin Lee, and colleagues at Kyung Hee University.

[Image of shingles rash and a heart, symbolizing the connection between the two. © Imago / Pond5 Images / M150AIP934]

While more research is needed, these findings underscore the potential for vaccination to play a broader role in promoting cardiovascular health and addressing health disparities worldwide.

Beyond the Rash: Unpacking the Shingles-heart Disease Connection

The surprising link between the herpes zoster (shingles) vaccine and heart health is causing excitement in the medical community. While the primary purpose of the vaccine is to prevent shingles, a painful and often debilitating condition, recent research reveals that the benefits may extend far beyond rash prevention. This article delves deeper into these findings,exploring why this connection exists and what it means for your health.

As highlighted in the initial study published in the European Heart Journal, the herpes zoster vaccine appears to offer meaningful protection against cardiovascular events. This adds to the body of knowledge already suggesting a potential impact of the varicella-zoster virus, the culprit behind both chickenpox and shingles, on the cardiovascular system.The twelve-year study, involving over two million participants, provides compelling evidence of a protective effect. Recent studies also indicate that corona vaccination may also reduce the risk of strokes, perhaps paving the way for more research into vaccine benefits [[1]].

Why the Link? Exploring the Mechanisms

The precise mechanisms behind the shingles vaccine’s impact on heart health are still under investigation, but several theories have emerged. One possibility is that preventing shingles reduces chronic inflammation in the body. Shingles, itself, can trigger inflammation, and chronic inflammation is known to contribute to the development of heart disease.

Another theory centers on the virus’s direct impact on the cardiovascular system. The varicella-zoster virus,even when dormant,might subtly affect blood vessels,potentially increasing the risk of cardiovascular events. By preventing shingles, the vaccine could also mitigate these effects. Additionally, the study in South Korea suggests the vaccine can reduce the overall risk of cardiovascular events [[2]].

Real-World Implications: Benefits and practical Tips

The research findings, especially with the emphasis on a reduction in cardiovascular events, have practical implications for individuals. Here are some key takeaways:

Vaccination is Key: For those aged 50 and older, the CDC strongly recommends getting the shingles vaccine, even if you’ve had shingles before. If you’ve had chickenpox,the virus remains in your body,increasing your risk of shingles later in life.
Consider Your Risk Factors: The study suggests that people with existing heart disease risk factors (smoking, poor diet, lack of exercise) may experience even greater benefits from the vaccine.
Discuss with Your doctor: Talk to your healthcare provider about your individual risk factors and the best vaccination strategy for you.
Two Doses are necessary: The current proposal for the recombinant zoster vaccine (Shingrix) is two doses, given a few months apart.

According to a new study, the shingles vaccine may reduce the risk of heart disease for up to eight years post-vaccination [[1]]. The findings offer a glimmer of hope in the ongoing fight against cardiovascular diseases,a leading cause of death globally [[3]].

Case Studies and Further Perspectives

While large-scale studies like the one conducted in South Korea provide valuable insights,real-world case studies can further illustrate the impact. sadly, documented case studies detailing the impact of shingles vaccination directly on cardiovascular outcomes are currently limited. However, anecdotal reports from physicians and patients highlight the potential for the vaccine to improve overall health and well-being.

One critically important outlook to consider is that of cardiologists and infectious disease specialists. Many acknowledge the potential link, emphasizing the need for ongoing research to confirm these findings across diverse populations. Further studies are needed to confirm whether the positive effects of the vaccine are universal and if there are specific risk factors that correlate with a higher benefit. Further assessments are planned to analyze diffrent types of vaccines to understand the broader implications for heart disease prevention.

Myths vs. Facts Regarding Shingles and the Vaccine

Several myths surround shingles and its vaccine. To shed light on the realities,here’s a breakdown:

Myth: You can’t get shingles if you’ve never had chickenpox.
Fact: Chickenpox is the source of the virus, and you can’t get shingles unless you had chickenpox.
Myth: The shingles vaccine guarantees you won’t get shingles.
Fact: The vaccine substantially reduces your risk of shingles and reduces the severity of the condition if you do get it.
Myth: The shingles vaccine is only for people who have had shingles.
Fact: The vaccine is recommended for people 50 and older, irrespective of whether they’ve had shingles.

Getting vaccinated can significantly decrease the risk of severe cardiovascular events, potentially saving lives. Addressing health disparities through vaccination is a growing area of focus because the vaccine could help compensate for disparities in healthcare access and outcomes.

Frequently Asked questions

Here are some frequently asked questions about the shingles vaccine and its link to heart health:

Q: Can the shingles vaccine really protect my heart?

A: Preliminary studies suggest a link between the shingles vaccine and reduced cardiovascular risk. More research is underway to confirm these findings.

Q: Is the shingles vaccine safe?

A: Yes, the shingles vaccine is considered safe and effective. it is recommended for adults 50 and older.

Q: If I’ve already had a heart attack, should I get the shingles vaccine?

A: consult your doctor. The vaccine may offer additional benefits. Based on the study findings,the vaccine is recommended for people over 50 years of age.

Q: What are the side effects of the shingles vaccine?

A: Common side effects are mild, include soreness at the injection site, fatigue, and headache.

Q: Does this mean the shingles vaccine can replace othre heart health measures?

A: No. The shingles vaccine is a valuable measure, but it should be used in conjunction with a healthy lifestyle, exercise, and medical interventions as recommended by your physician.

Table of Contents